Systemic therapies in psoriasis: an update on newly approved and pipeline biologics and oral treatments

  • Cutis. 2019 Aug;104(2S):17-20.
Annika Havnaer  1 ,  Jeffrey M Weinberg  2 ,  George Han  2
Affiliations
  • 1. Icahn School of Medicine at Mount Sinai, New York, New York, and Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
  • 2. Icahn School of Medicine at Mount Sinai, New York, New York, USA.
PMID: 31634386
Abstract

Although there are numerous biologics and several oral treatments for psoriasis, a number of promising systemic therapies are on the horizon. Knowledge of these medications might help guide our treatment approach to the patient with psoriasis. This article provides an update on the most recent (as of 2019) approved therapies and medications in the pipeline for moderate to severe plaque psoriasis, with a focus on systemic agents in phase 3 clinical trials.

Products